Colorectal Cancer Diagnostics Market
Colorectal Cancer Diagnostics Market Report By Test Type (Colorectal Cancer FOB Tests, Colorectal Cancer CTC Tests, Colorectal Cancer CEA Tests, Colorectal Cancer BRAF V600 Mutation Tests, KRAS Mutation Tests), By End User - Forecast to 2021 to 2031
Analysis of Colorectal Cancer Diagnostics market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
FREE CustomizationColorectal Cancer Diagnostics Market Outlook
The global colorectal cancer diagnostics market and have predicted to industry expansion at a CAGR of 8.5% over the decade.
| Report Attributes | Details |
|---|---|
| Global Market Value in 2020 | US$ 2 Bn |
| Projected Market Value for 2031 | US$ 4.5 Bn |
| CAGR (2021 to 2031) | 8.5% |
| Fastest-Growing Regional Markets | China and India |
Fact.MR, a market research and competitive intelligence provider, has compiled a comprehensive assessment of various aspects that influence market growth and revenue potential. The market for colorectal cancer diagnostics was worth US$ 2 Bn in 2020, and is predicted to rise 2.2X by the end of the decade.
Demand Analysis of Colorectal Cancer Diagnostics (2016 to 2020) Vs Market Projections (2021 to 2031)
Colorectal cancer is also known as colon cancer or rectal cancer based on the nature of origin in the body. The cancers are very similar in most aspects, hence, colon cancer diagnostics and rectal cancer diagnostics are researched and developed on the same lines as that of colorectal cancer.
Instances of colorectal cancer have been seeing an increase over the past decade, and this can be attributed to lifestyle disorders, aging population, and improper diet habits. WHO (World Health Organization) has also stated that, there would be a 70% rise in the prevalence of colorectal cancer cases worldwide by 2030.
As the number of cases rises, demand for effective treatment and diagnosis is also expected to follow a similar trend. Demand for colorectal cancer diagnostics is expected to rise at a CAGR of 8.5% over the decade.
Which Tests are Most Common for Colorectal Cancer Diagnostics?
There are many tests prevalent in the industry to diagnose colorectal cancer. Every test has its own specific nature of indicator. Of all of the tests, FOB tests are expected to see dominant demand over the forecast period and rake in majority of revenue. CTC tests for colorectal cancer diagnostics are expected to follow and bring in the second-highest revenue share.
Demand for immunochemistry tests for colorectal cancer diagnostics is predicted to rise at the highest CAGR over the next ten years. BRAF tests for colorectal cancer diagnostics are not as common and are anticipated to rise at the lowest CAGR among all other tests.
What is the Outlook for the Colorectal Cancer Treatment Market?
As prevalence of colorectal cancer increases, demand for its treatment is also expected to see a significant increase over the years. Key providers of colorectal cancer diagnostics are focusing on creating effective and optimal diagnostic solutions that would be crucial in treatment of the disease.
Colorectal cancer medicine manufacturers are also focusing on developing drugs and pharmaceuticals that would aid in the treatment process. This is expected to drive demand in the colorectal cancer medication market.
Screening and imaging play a vital role in the diagnosis of colorectal cancer to understand the extent of tumor-affected area. In-vitro colorectal cancer screening tests are expected to see major rise in demand over the next ten years as instances of colorectal cancer rise.
Growth of the colorectal cancer diagnostics devices market is directly proportional to the growth of the global colorectal cancer diagnostics market, and is expected to rise at a similar pace in terms of demand.
Why is Popularity of Colorectal Cancer Therapeutics Increasing?
With incidence of colorectal cancer rising, demand for therapeutics to treat the condition is also anticipated to rise. Colorectal cancer immunotherapy is one of the most significant types of treatment that is popular across the world.
Demand for colorectal cancer immunotherapy is anticipated to be very notable over the decade, and this can be attributed to widespread availability of immunotherapy drugs all over the globe.
For advanced stages of colorectal cancers, different therapies are used based on the risk factor. Colorectal cancer targeted therapy and colorectal cancer chemotherapy are majorly used for advanced stage cases.
Which Regions are Expected to Provide Beneficial Opportunities for Colorectal Cancer Diagnostic Providers?
This research details the global colorectal cancer diagnostics industry across regions such as North America, Latin America, Europe, APAC, and MEA.
North America is anticipated to hold its position as a dominant shareholder in demand as well as revenue terms. Dominance is asserted by increasing incidence of colorectal cancer and presence of prominent players across the region.
Demand for colorectal cancer diagnostics in the European region is expected to rise at a significant CAGR owing to high adoption of novel procedures for treatment and diagnosis backed by increasing research.
The market in Asia Pacific is also slated for notable expansion, and this growth can be attributed to increasing adoption of diagnostic procedures as awareness about colorectal cancer increases. Demand in India and China is expected to be significantly higher than the other nations in the region.
Rising incidence of colorectal cancer in the MEA region is expected to drive demand for colorectal cancer diagnostics in the region. Demand is expected to rise at a steady pace initially.
Country-wise Analysis
How is the U.S. Colorectal Cancer Diagnostics Market Shaping Up?
Colorectal cancer is the second-most-common cancer to cause death in the U.S., and this makes it a major cause of concern for the nation. The U.S. is seeing a substantial rise in cases of colorectal cancer, and this can be attributed to sedentary lifestyle and poor eating & dietary habits which are prevalent in the nation.
Demand for colorectal cancer diagnostics is also driven by the presence of prominent players in the country and early adoption of novel diagnostic and treatment solutions.
Why is Demand for Colorectal Cancer Diagnostics High in China?
Demand for colorectal cancer diagnostics in China is expected to evolve at a high CAGR over the forecast period. Increase in demand can be attributed to rising awareness about the disease, prevalence of cost-effective diagnosis, and rising medical tourism.
Over the coming years, the market in China is expected to be substantially larger than what it is in terms of size as well as revenue.
Category-wise Analysis
Which Establishments Lead Demand for Colorectal Cancer Diagnostics?
Hospital-associated labs hold a dominant revenue share in the global colorectal cancer diagnostics industry. Demand for colorectal cancer diagnostics at cancer research institutes is anticipated to rise at the highest CAGR over the next ten years.
Use of colorectal cancer diagnostics in independent diagnostic laboratories is expected to see major increase, especially in emerging economies, due to increasing affordability of diagnostic devices and instruments.
COVID-19 Pandemic Evaluation
The screening and diagnosis of colorectal cancer saw a major drop during the pandemic period, which is a cause of concern, since diagnosis is a crucial aspect to deal with the disease effectively. Due to the pandemic, it was not possible to run extensive diagnosis of various health issues, and that created some major issues for people suffering from different health conditions.
In the post-pandemic era, focus on diagnosis of colorectal cancer is expected to see a major rise as WHO has predicted a massive rise in cases for this decade. More diagnostic providers will be targeting cost-effective methods to boost sales of tests and increase diagnostic numbers.
Competitive Landscape
Providers of colorectal cancer diagnosis are investing in the research & development of devices and instruments that would aid in diagnosis and treatment more effectively and efficiently.
- Researchers at the University of Warwick have developed a new deep learning algorithm that is capable of identifying molecular pathways and mutations that result in the development of colorectal cancer. This could be a breakthrough in treating colorectal cancer patients.
- Research at the Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology has discovered a small molecule - RGX-202 – which, in future, could be administered along with therapy treatment to starve colorectal cancer metastasis.
- Researchers at the Hollings Cancer Center are also studying the increasing incidence of colorectal cancer among young individuals and prevalence in minorities. This research could be crucial in controlling the prevalence of colorectal cancer and aid in providing better preventive diagnostic and treatment solutions.
Colorectal Cancer Diagnostics Industry Report Scope
| Report Attributes | Details |
|---|---|
| Forecast Period | 2021 to 2031 |
| Historical Data Available for | 2016 to 2020 |
| Market Analysis | Units for Volume and US$ Mn for Value |
| Key Regions Covered | North America; Latin America; Europe; APEJ; MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, U.K., France, Spain, Italy, China, Japan, South Korea, India, Indonesia, Malaysia, Singapore, Australia, New Zealand, Turkey, South Africa, and GCC Countries |
| Key Market Segments Covered | Test Type, End User, Region |
| Key Companies Profiled | Danaher Corporation; Rosetta Genomics; Epigenomics AG; Exact Science Corporation; Pathway Genomics Corporation; Biocept Inc.; Cancer Genetics Inc. |
| Pricing | Available upon Request |
Key Segments Covered in Colorectal Cancer Diagnostics Industry Survey
-
By Test Type:
- Colorectal Cancer FOB Tests
- Colorectal Cancer CTC Tests
- Colorectal Cancer CEA Tests
- Colorectal Cancer BRAF V600 Mutation Tests
- Colorectal Cancer Immunohistochemistry Tests
- C-kit/CD117
- KRAS Mutation Tests
- Others
-
By End User:
- Hospital-associated Labs
- Independent Diagnostic Laboratories
- Cancer Research Institutes
- Others
Table of Content
- 1. Global Market to Executive Summary
- 2. Global Market Overview
- 3. Global Market Analysis and Forecast By Test Type
- 3.1. FOB
- 3.2. CTC Tests
- 3.3. BRAF V600 Mutations
- 3.4. CEA Tests
- 3.5. C to kit/CD117
- 3.6. KRAS Mutation Tests
- 3.7. Immunohistochemistry
- 3.8. Others
- 4. Global Market Analysis and Forecast By End User
- 4.1. Hospital Associated Labs
- 4.2. Independent Diagnostic Laboratories
- 4.3. Cancer Research Institutes Colorectal Cancer
- 4.4. Others
- 5. Global Market Analysis and Forecast By Region
- 5.1. North America Market
- 5.2. Latin America Market
- 5.3. Europe Market
- 5.4. Japan Market
- 5.5. APEJ Market
- 5.6. MEA Market
- 6. North America Market Analysis and Forecast, By Country, 2021 to 2031
- 7. Latin America Market Analysis and Forecast, By Country, 2021 to 2031
- 8. Europe Market Analysis and Forecast, By Country, 2021 to 2031
- 9. Japan Market Analysis and Forecast, By Country, 2021 to 2031
- 10. APEJ Market Analysis and Forecast, By Country, 2021 to 2031
- 11. MEA Market Analysis and Forecast, By Country, 2021 to 2031
- 12. Global Market Company/Manufactures/Distributors/Suppliers Profile and Revenue Projections
- 12.1. Company Share Analysis
- 12.2. Abbott Laboratories
- 12.3. Agilent Technologies, Inc.
- 12.4. Bio Rad Laboratories Inc.
- 12.5. F. Hoffmann to La Roche Ltd.
- 12.6. Thermo Fisher Scientific Inc.
- 13. Research Methodology
- 14. Secondary and Primary Sources
- 15. Assumptions and Acronyms
- 16. Disclaimer
List Of Table
TABLE 1 Global Value (US$ Mn), 2016 to 2020
TABLE 2 Global Value (US$ Mn), 2021 to 2031
TABLE 3 Global Value (US$ Mn) and Y-o-Y, 2015 to 2022
TABLE 4 Global FOB Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 5 Global FOB Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 6 Global FOB Segment Market Share, By Region 2016 to 2020
TABLE 7 Global FOB Segment Market Share, By Region 2021 to 2031
TABLE 8 Global FOB Segment Y-o-Y, By Region 2015 to 2022
TABLE 9 Global CTC Tests Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 10 Global CTC Tests Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 11 Global CTC Tests Segment Market Share, By Region 2016 to 2020
TABLE 12 Global CTC Tests Segment Market Share, By Region 2021 to 2031
TABLE 13 Global CTC Tests Segment Y-o-Y, By Region 2015 to 2022
TABLE 14 Global BRAF V600 Mutations Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 15 Global BRAF V600 Mutations Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 16 Global BRAF V600 Mutations Segment Market Share, By Region 2016 to 2020
TABLE 17 Global BRAF V600 Mutations Segment Market Share, By Region 2021 to 2031
TABLE 18 Global BRAF V600 Mutations Segment Y-o-Y, By Region 2015 to 2022
TABLE 19 Global CEA Tests Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 20 Global CEA Tests Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 21 Global CEA Tests Segment Market Share, By Region 2016 to 2020
TABLE 22 Global CEA Tests Segment Market Share, By Region 2021 to 2031
TABLE 23 Global CEA Tests Segment Y-o-Y, By Region 2015 to 2022
TABLE 24 Global C-kit/CD117 Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 25 Global C-kit/CD117 Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 26 Global C-kit/CD117 Segment Market Share, By Region 2016 to 2020
TABLE 27 Global C-kit/CD117 Segment Market Share, By Region 2021 to 2031
TABLE 28 Global C-kit/CD117 Segment Y-o-Y, By Region 2015 to 2022
TABLE 29 Global KRAS Mutation Tests Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 30 Global KRAS Mutation Tests Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 31 Global KRAS Mutation Tests Segment Market Share, By Region 2016 to 2020
TABLE 32 Global KRAS Mutation Tests Segment Market Share, By Region 2021 to 2031
TABLE 33 Global KRAS Mutation Tests Segment Y-o-Y, By Region 2015 to 2022
TABLE 34 Global Immunohistochemistry Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 35 Global Immunohistochemistry Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 36 Global Immunohistochemistry Segment Market Share, By Region 2016 to 2020
TABLE 37 Global Immunohistochemistry Segment Market Share, By Region 2021 to 2031
TABLE 38 Global Immunohistochemistry Segment Y-o-Y, By Region 2015 to 2022
TABLE 39 Global Others Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 40 Global Others Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 41 Global Others Segment Market Share, By Region 2016 to 2020
TABLE 42 Global Others Segment Market Share, By Region 2021 to 2031
TABLE 43 Global Others Segment Y-o-Y, By Region 2015 to 2022
TABLE 44 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 45 Global Hospital Associated Labs Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 46 Global Hospital Associated Labs Segment Market Share, By Region 2016 to 2020
TABLE 47 Global Hospital Associated Labs Segment Market Share, By Region 2021 to 2031
TABLE 48 Global Hospital Associated Labs Segment Y-o-Y, By Region 2015 to 2022
TABLE 49 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 50 Global Independent Diagnostic Laboratories Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 51 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2016 to 2020
TABLE 52 Global Independent Diagnostic Laboratories Segment Market Share, By Region 2021 to 2031
TABLE 53 Global Independent Diagnostic Laboratories Segment Y-o-Y, By Region 2015 to 2022
TABLE 54 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 55 Global Cancer Research Institutes Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 56 Global Cancer Research Institutes Segment Market Share, By Region 2016 to 2020
TABLE 57 Global Cancer Research Institutes Segment Market Share, By Region 2021 to 2031
TABLE 58 Global Cancer Research Institutes Segment Y-o-Y, By Region 2015 to 2022
TABLE 59 Global Others Segment Value (US$ Mn), By Region 2016 to 2020
TABLE 60 Global Others Segment Value (US$ Mn), By Region 2021 to 2031
TABLE 61 Global Others Segment Market Share, By Region 2016 to 2020
TABLE 62 Global Others Segment Market Share, By Region 2021 to 2031
TABLE 63 Global Others Segment Y-o-Y, By Region 2015 to 2022
TABLE 64 North America Value (US$ Mn), By Test Type 2016 to 2020
TABLE 65 North America Value (US$ Mn), By Test Type 2021 to 2031
TABLE 66 North America Value (US$ Mn), By End User 2016 to 2020
TABLE 67 North America Value (US$ Mn), By End User 2021 to 2031
TABLE 68 Latin America Value (US$ Mn), By Test Type 2016 to 2020
TABLE 69 Latin America Value (US$ Mn), By Test Type 2021 to 2031
TABLE 70 Latin America Value (US$ Mn), By End User 2016 to 2020
TABLE 71 Latin America Value (US$ Mn), By End User 2021 to 2031
TABLE 72 Europe Value (US$ Mn), By Test Type 2016 to 2020
TABLE 73 Europe Value (US$ Mn), By Test Type 2021 to 2031
TABLE 74 Europe Value (US$ Mn), By End User 2016 to 2020
TABLE 75 Europe Value (US$ Mn), By End User 2021 to 2031
TABLE 76 Japan Value (US$ Mn), By Test Type 2016 to 2020
TABLE 77 Japan Value (US$ Mn), By Test Type 2021 to 2031
TABLE 78 Japan Value (US$ Mn), By End User 2016 to 2020
TABLE 79 Japan Value (US$ Mn), By End User 2021 to 2031
TABLE 80 APEJ Value (US$ Mn), By Test Type 2016 to 2020
TABLE 81 APEJ Value (US$ Mn), By Test Type 2021 to 2031
TABLE 82 APEJ Value (US$ Mn), By End User 2016 to 2020
TABLE 83 APEJ Value (US$ Mn), By End User 2021 to 2031
TABLE 84 MEA Value (US$ Mn), By Test Type 2016 to 2020
TABLE 85 MEA Value (US$ Mn), By Test Type 2021 to 2031
TABLE 86 MEA Value (US$ Mn), By End User 2016 to 2020
TABLE 87 MEA Value (US$ Mn), By End User 2021 to 2031
TABLE 88 US Value (US$ Mn), By Test Type 2016 to 2020
TABLE 89 US Value (US$ Mn), By Test Type 2021 to 2031
TABLE 90 US Value (US$ Mn), By End User 2016 to 2020
TABLE 91 US Value (US$ Mn), By End User 2021 to 2031
TABLE 92 Canada Value (US$ Mn), By Test Type 2016 to 2020
TABLE 93 Canada Value (US$ Mn), By Test Type 2021 to 2031
TABLE 94 Canada Value (US$ Mn), By End User 2016 to 2020
TABLE 95 Canada Value (US$ Mn), By End User 2021 to 2031
TABLE 96 Brazil Value (US$ Mn), By Test Type 2016 to 2020
TABLE 97 Brazil Value (US$ Mn), By Test Type 2021 to 2031
TABLE 98 Brazil Value (US$ Mn), By End User 2016 to 2020
TABLE 99 Brazil Value (US$ Mn), By End User 2021 to 2031
TABLE 100 Mexico Value (US$ Mn), By Test Type 2016 to 2020
TABLE 101 Mexico Value (US$ Mn), By Test Type 2021 to 2031
TABLE 102 Mexico Value (US$ Mn), By End User 2016 to 2020
TABLE 103 Mexico Value (US$ Mn), By End User 2021 to 2031
TABLE 104 Argentina Value (US$ Mn), By Test Type 2016 to 2020
TABLE 105 Argentina Value (US$ Mn), By Test Type 2021 to 2031
TABLE 106 Argentina Value (US$ Mn), By End User 2016 to 2020
TABLE 107 Argentina Value (US$ Mn), By End User 2021 to 2031
TABLE 108 Germany Value (US$ Mn), By Test Type 2016 to 2020
TABLE 109 Germany Value (US$ Mn), By Test Type 2021 to 2031
TABLE 110 Germany Value (US$ Mn), By End User 2016 to 2020
TABLE 111 Germany Value (US$ Mn), By End User 2021 to 2031
TABLE 112 UK Value (US$ Mn), By Test Type 2016 to 2020
TABLE 113 UK Value (US$ Mn), By Test Type 2021 to 2031
TABLE 114 UK Value (US$ Mn), By End User 2016 to 2020
TABLE 115 UK Value (US$ Mn), By End User 2021 to 2031
TABLE 116 France Value (US$ Mn), By Test Type 2016 to 2020
TABLE 117 France Value (US$ Mn), By Test Type 2021 to 2031
TABLE 118 France Value (US$ Mn), By End User 2016 to 2020
TABLE 119 France Value (US$ Mn), By End User 2021 to 2031
TABLE 120 Spain Value (US$ Mn), By Test Type 2016 to 2020
TABLE 121 Spain Value (US$ Mn), By Test Type 2021 to 2031
TABLE 122 Spain Value (US$ Mn), By End User 2016 to 2020
TABLE 123 Spain Value (US$ Mn), By End User 2021 to 2031
TABLE 124 Italy Value (US$ Mn), By Test Type 2016 to 2020
TABLE 125 Italy Value (US$ Mn), By Test Type 2021 to 2031
TABLE 126 Italy Value (US$ Mn), By End User 2016 to 2020
TABLE 127 Italy Value (US$ Mn), By End User 2021 to 2031
TABLE 128 Nordic Value (US$ Mn), By Test Type 2016 to 2020
TABLE 129 Nordic Value (US$ Mn), By Test Type 2021 to 2031
TABLE 130 Nordic Value (US$ Mn), By End User 2016 to 2020
TABLE 131 Nordic Value (US$ Mn), By End User 2021 to 2031
TABLE 132 Japan Value (US$ Mn), By Test Type 2016 to 2020
TABLE 133 Japan Value (US$ Mn), By Test Type 2021 to 2031
TABLE 134 Japan Value (US$ Mn), By End User 2016 to 2020
TABLE 135 Japan Value (US$ Mn), By End User 2021 to 2031
TABLE 136 China Value (US$ Mn), By Test Type 2016 to 2020
TABLE 137 China Value (US$ Mn), By Test Type 2021 to 2031
TABLE 138 China Value (US$ Mn), By End User 2016 to 2020
TABLE 139 China Value (US$ Mn), By End User 2021 to 2031
TABLE 140 India Value (US$ Mn), By Test Type 2016 to 2020
TABLE 141 India Value (US$ Mn), By Test Type 2021 to 2031
TABLE 142 India Value (US$ Mn), By End User 2016 to 2020
TABLE 143 India Value (US$ Mn), By End User 2021 to 2031
TABLE 144 Malaysia Value (US$ Mn), By Test Type 2016 to 2020
TABLE 145 Malaysia Value (US$ Mn), By Test Type 2021 to 2031
TABLE 146 Malaysia Value (US$ Mn), By End User 2016 to 2020
TABLE 147 Malaysia Value (US$ Mn), By End User 2021 to 2031
TABLE 148 Thailand Value (US$ Mn), By Test Type 2016 to 2020
TABLE 149 Thailand Value (US$ Mn), By Test Type 2021 to 2031
TABLE 150 Thailand Value (US$ Mn), By End User 2016 to 2020
TABLE 151 Thailand Value (US$ Mn), By End User 2021 to 2031
TABLE 152 Singapore Value (US$ Mn), By Test Type 2016 to 2020
TABLE 153 Singapore Value (US$ Mn), By Test Type 2021 to 2031
TABLE 154 Singapore Value (US$ Mn), By End User 2016 to 2020
TABLE 155 Singapore Value (US$ Mn), By End User 2021 to 2031
TABLE 156 Australia Value (US$ Mn), By Test Type 2016 to 2020
TABLE 157 Australia Value (US$ Mn), By Test Type 2021 to 2031
TABLE 158 Australia Value (US$ Mn), By End User 2016 to 2020
TABLE 159 Australia Value (US$ Mn), By End User 2021 to 2031
TABLE 160 GCC Countries Value (US$ Mn), By Test Type 2016 to 2020
TABLE 161 GCC Countries Value (US$ Mn), By Test Type 2021 to 2031
TABLE 162 GCC Countries Value (US$ Mn), By End User 2016 to 2020
TABLE 163 GCC Countries Value (US$ Mn), By End User 2021 to 2031
TABLE 164 South Africa Value (US$ Mn), By Test Type 2016 to 2020
TABLE 165 South Africa Value (US$ Mn), By Test Type 2021 to 2031
TABLE 166 South Africa Value (US$ Mn), By End User 2016 to 2020
TABLE 167 South Africa Value (US$ Mn), By End User 2021 to 2031
TABLE 168 Nigeria Value (US$ Mn), By Test Type 2016 to 2020
TABLE 169 Nigeria Value (US$ Mn), By Test Type 2021 to 2031
TABLE 170 Nigeria Value (US$ Mn), By End User 2016 to 2020
TABLE 171 Nigeria Value (US$ Mn), By End User 2021 to 2031
TABLE 172 Israel Value (US$ Mn), By Test Type 2016 to 2020
TABLE 173 Israel Value (US$ Mn), By Test Type 2021 to 2031
TABLE 174 Israel Value (US$ Mn), By End User 2016 to 2020
TABLE 175 Israel Value (US$ Mn), By End User 2021 to 2031
TABLE 176 Abbott Laboratories Value (US$ Mn), By Test Type 2021 to 2031
TABLE 177 Abbott Laboratories Value (US$ Mn), By End User 2021 to 2031
TABLE 178 Agilent Technologies, Inc. Value (US$ Mn), By Test Type 2021 to 2031
TABLE 179 Agilent Technologies, Inc. Value (US$ Mn), By End User 2021 to 2031
TABLE 180 Bio Rad Laboratories Inc. Value (US$ Mn), By Test Type 2021 to 2031
TABLE 181 Bio Rad Laboratories Inc. Value (US$ Mn), By End User 2021 to 2031
TABLE 182 F. Hoffmann-La Roche Ltd. Value (US$ Mn), By Test Type 2021 to 2031
TABLE 183 F. Hoffmann-La Roche Ltd. Value (US$ Mn), By End User 2021 to 2031
TABLE 184 Thermo Fisher Scientific Inc. Value (US$ Mn), By Test Type 2021 to 2031
TABLE 185 Thermo Fisher Scientific Inc. Value (US$ Mn), By End User 2021 to 2031
List Of Figures
FIG. 1 Global Market Value (US$ Mn), 2016 to 2020
FIG. 2 Global Market Value (US$ Mn) Forecast, 2017 to 2022
FIG. 3 Global Market Value (US$ Mn) and Y-o-Y, 2021 to 2031
FIG. 4 Global FOB Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 5 Global FOB Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 6 Global FOB Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 7 Global CTC Tests Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 8 Global CTC Tests Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 9 Global CTC Tests Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 10 Global BRAF V600 Mutations Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 11 Global BRAF V600 Mutations Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 12 Global BRAF V600 Mutations Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 13 Global CEA Tests Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 14 Global CEA Tests Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 15 Global CEA Tests Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 16 Global C-kit/CD117 Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 17 Global C-kit/CD117 Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 18 Global C-kit/CD117 Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 19 Global KRAS Mutation Tests Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 20 Global KRAS Mutation Tests Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 21 Global KRAS Mutation Tests Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 22 Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 23 Global Immunohistochemistry Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 24 Global Immunohistochemistry Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 25 Global Others Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 26 Global Others Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 27 Global Others Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 28 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 29 Global Hospital Associated Labs Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 30 Global Hospital Associated Labs Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 31 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 32 Global Independent Diagnostic Laboratories Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 33 Global Independent Diagnostic Laboratories Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 34 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 35 Global Cancer Research Institutes Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 36 Global Cancer Research Institutes Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 37 Global Others Segment Market Value (US$ Mn) By Region, 2016 to 2020
FIG. 38 Global Others Segment Market Value (US$ Mn) By Region, 2017 to 2022
FIG. 39 Global Others Segment Y-o-Y Growth Rate, By Region, 2021 to 2031
FIG. 40 North America Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 41 North America Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 42 North America Market Value (US$ Mn), By End User 2016 to 2020
FIG. 43 North America Market Value (US$ Mn), By End User 2017 to 2022
FIG. 44 Latin America Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 45 Latin America Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 46 Latin America Market Value (US$ Mn), By End User 2016 to 2020
FIG. 47 Latin America Market Value (US$ Mn), By End User 2017 to 2022
FIG. 48 Europe Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 49 Europe Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 50 Europe Market Value (US$ Mn), By End User 2016 to 2020
FIG. 51 Europe Market Value (US$ Mn), By End User 2017 to 2022
FIG. 52 Japan Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 53 Japan Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 54 Japan Market Value (US$ Mn), By End User 2016 to 2020
FIG. 55 Japan Market Value (US$ Mn), By End User 2017 to 2022
FIG. 56 APEJ Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 57 APEJ Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 58 APEJ Market Value (US$ Mn), By End User 2016 to 2020
FIG. 59 APEJ Market Value (US$ Mn), By End User 2017 to 2022
FIG. 60 MEA Market Value (US$ Mn), By Test Type 2016 to 2020
FIG. 61 MEA Market Value (US$ Mn), By Test Type 2017 to 2022
FIG. 62 MEA Market Value (US$ Mn), By End User 2016 to 2020
FIG. 63 MEA Market Value (US$ Mn), By End User 2017 to 2022
- FAQs -
Which type of test is expected to be widely adopted for colorectal cancer diagnostics?
FOB tests for colorectal cancer diagnostics are anticipated to be widely adopted over the next ten years.
What metrics are listed for the global colorectal cancer diagnostics market for the decade?
The global colorectal cancer diagnostics market is anticipated to rise at a healthy CAGR of 8.5% through 2031.
What was the revenue from colorectal cancer diagnostics in 2020?
In 2020, the global market for colorectal cancer diagnostics was worth around US$ 2 Bn.
As per the research what will the market be worth by the end of 2031?
By the end of 2031 the global colorectal cancer diagnostics industry is estimated to be valued at around US$ 4.5 Bn.
What does the report reveal about colorectal cancer immunotherapy?
Demand for colorectal cancer immunotherapy is anticipated to be significant owing to high availability of immunotherapy drugs.
Who are the prime providers of colorectal cancer diagnostics?
Key players such as Danaher Corporation, Rosetta Genomics, Epigenomics AG, Exact Science Corporation, Pathway Genomics Corporation, Biocept Inc., Cancer Genetics Inc., and Foundation Medicine Inc. are key players operating in this marketplace.
What factors are expected to influence demand for colorectal cancer diagnostics?
Rising prevalence of cancers, poor lifestyle choices, affordable diagnostic procedures, and increasing awareness are some of the major factors influencing demand.
Colorectal Cancer Diagnostics Market